Bird Flu Vaccine Trial Initiated in the UK
Clare Howard was among the first individuals vaccinated against the H5N1 bird flu strain as part of a new UK trial aiming to develop protection against a potential pandemic.
The vaccine specifically targets the H5N1 strain, which has caused widespread infections in bird populations globally and has also been detected in some mammalian species.
The UK Health Security Agency currently assesses the risk to humans as low, with nearly all human infections linked to close contact with infected animals.
This vaccine employs mRNA technology, similar to that used in Covid-19 vaccines, allowing for rapid and scalable production in the event of a pandemic.
The trial seeks to enroll individuals working in the poultry industry or those aged over 65, identified as the groups most at risk.
Clare Howard, a Hampshire resident who has raised chickens for years, was among the first volunteers to receive the vaccine at a clinic in Southampton.
"It was quite easy and it could be something that ultimately proves incredibly important," she said.
Trial Scope and Expert Insights
The large-scale trial plans to recruit 4,000 volunteers, with approximately 75% enrolled across 26 sites in England and Scotland, and the remainder in the United States.
Dr Rebecca Clark, the trial's national coordinating investigator based at Layton Medical Centre in Blackpool, highlighted the evolving nature of the strain.
"The strain is evolving and spreading across animal species," she stated. "Although it does not yet move easily between humans, we have to treat human-to-human transmission as a real possibility."
"This trial is our proactive attempt to shield against that possibility, and any future pandemic that could emerge from it."
Since 2024, there have been 116 confirmed human cases worldwide, almost all linked to close contact with infected animals.
The study aims to evaluate the vaccine's safety and its ability to elicit a strong immune response. If successful, the vaccine could be licensed for use when necessary.
Professor Lucy Chappell, chief scientific adviser at the Department of Health and Social Care and CEO of the National Institute for Health and Care Research, remarked that the trial is enhancing pandemic preparedness.
"This trial is bolstering our pandemic resilience," she said.
If required, the vaccine would be produced at Moderna's new manufacturing facility in Harwell, Oxfordshire, which currently produces Covid vaccines for the UK.
The plant has an annual capacity of 100 million doses, which could be increased to 250 million doses during a pandemic.
Advantages of mRNA Vaccine Technology
Traditional flu vaccines are produced by growing the virus in eggs, a process complicated by virulent avian flu strains that can kill the eggs used in manufacturing.
During the Covid-19 pandemic, mRNA vaccines demonstrated high effectiveness in preventing severe illness and offered rapid adaptability as viral strains evolved.
Flu pandemics are considered inevitable, though the timing of the next global outbreak remains uncertain. The influenza virus continuously evolves, necessitating annual flu vaccinations.
A flu pandemic occurs when the virus undergoes a significant shift, rather than a gradual drift, resulting in a strain to which humans have no natural immunity.
The last flu pandemic in 2009, known as swine flu, was relatively mild. However, the Spanish flu pandemic following World War I resulted in approximately 50 million deaths worldwide.
It remains uncertain whether H5N1 will be the strain responsible for the next flu pandemic.
Previous experimental vaccines targeting H5N1 have been developed. The author participated in a 2006 trial in Oxford; although the vaccine was safe, it did not demonstrate strong efficacy.
Since 2003, the World Health Organization has reported around 1,000 confirmed human cases of H5N1, with nearly half resulting in fatalities.
More recently, a strain circulating in the United States caused milder symptoms, primarily eye inflammation.
Funding and Global Access Commitments
In August 2025, the US government reduced funding for mRNA vaccines by $500 million after Health Secretary Robert F. Kennedy Jr., a vaccine skeptic, expressed concerns over the technology's risks for respiratory viruses.
The Coalition for Epidemic Preparedness Innovations (CEPI) has provided £40 million in funding to support this trial.
As part of the agreement, Moderna has committed to ensuring rapid and affordable vaccine supply to low- and middle-income countries during any future pandemic.
CEPI noted this commitment aims to prevent "vaccine nationalism" witnessed during the Covid-19 pandemic, when wealthy countries secured early vaccine supplies, leaving millions unprotected.
- Bird flu outbreak leads to imposed cull
- Should I worry about a bird flu pandemic?
- Cows in the US have bird flu - is it inching closer to humans?
